Logo
Login
$BTAIQ
$0.07 -$0.04 (37.11%) Close

Company Executives

$BTAIQ Management Team

Mr. Erik Kopp

Investor Relations

Age -
Compensation -
Sex Male

Dr. Peter Mueller

Lead Independent Chairman of the Board

Age 68
Compensation $150.4K USD
Sex Male

Dr. Vimal Mehta

President

Chief Executive Officer

Director

Age 64
Compensation $1.119M USD
Sex Male

Dr. Frank Yocca

Executive Vice President

Chief Scientific Officer

Age 69
Compensation $1.153M USD
Sex Male

Mr. Javier Rodriguez

Senior Vice President

Chief Legal Officer

Corporate Secretary

Age 53
Compensation $1.013M USD
Sex Male

Mr. Richard Steinhart

Chief Financial Officer

Senior Vice President

Age 68
Compensation $994.1K USD
Sex Male

Board of Directors

From the proxy statement filed Nov 12, 2025
Directors
8
serving now
Independent
7 of 7
stated in the proxy; 1 not stated
Average tenure
4.8 years
from year joined
CEO also chairs the board
No
Peter Mueller, Ph.D.
Director Age On board Independent Committees Other public boards 2024 pay Source
June Bray
72 2021
4 years
 Independent
Nominating and Corporate Governance Committee
Quince Therapeutics, Inc. $85,410
Sandeep Laumas, M.D.
57 2017
8 years
 Independent
Audit Committee · Chair Compensation Committee Nominating and Corporate Governance Committee
Bioxcel Therapeutics Inc., Unicycive Therapeutics Inc. $112,910
David Mack
55 2024
1 year
 Independent
Compensation Committee
None stated $215,619
Michael Miller
Not stated 2022
3 years
 Independent
Audit Committee
Puma Biotechnology Inc. $90,410
Rajiv Patni, M.D.
57 2025
0 years
 Independent None stated Quince Therapeutics, Inc. Not stated
Michal Votruba, M.D.
60 2019
6 years
 Independent
Audit Committee
None stated $90,410
Vimal Mehta, Ph.D.
CEO
 64 2017
8 years
 Not stated None stated None stated Paid as CEO
Peter Mueller, Ph.D.
Board chair
 69 2017
8 years
 Independent
Audit Committee Compensation Committee · Chair Nominating and Corporate Governance Committee · Chair
None stated $150,410

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

3 disclosed in the proxy filed Nov 12, 2025
BioXcel LLC
successor in interest to BioXcel Corporation, our former parent; majority owned and controlled by BioXcel Holdings, Inc.
Amount not stated
effective June 30, 2017

Asset contribution agreement under which BioXcel LLC contributed BXCL501, BXCL701, BXCL502 and BXCL702 candidates to us for share and cash consideration and milestone payments; no milestone payments were made in 2023 or 2024.

With BioXcel LLC Open in proxy
BioXcel LLC
successor in interest to BioXcel Corporation, our former parent; majority owned and controlled by BioXcel Holdings, Inc.
$1.3 million
2024 and 2023

Separation and shared services agreement under which BioXcel LLC provides drug discovery, CMC and general and administrative services; service charges recorded under it.

With BioXcel LLC Open in proxy
BioXcel LLC
successor in interest to BioXcel Corporation, our former parent; majority owned and controlled by BioXcel Holdings, Inc.
$18,000 per month
March 13, 2023 through December 31, 2024

Option under the Services Agreement to enter into a collaborative services agreement with BioXcel LLC for product identification using EvolverAI, for which we agreed to pay a monthly option fee.

With BioXcel LLC Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans